Provide your email for confirmation

Tell us a bit about yourself

country *

Please provide your email address

welcome to Rappler

Login

To share your thoughts

Don't have an account?

Login with email

Check your inbox

We just sent a link to your inbox. Click the link to continue signing in. Can’t find it? Check your spam & junk mail.

Didn't get a link?

Use password?

Login with email

Reset password?

Please use the email you used to register and we will send you a link to reset your password

Check your inbox

We just sent a link to your inbox. Click the link to continue resetting your password. Can’t find it? Check your spam & junk mail.

Didn't get a link?

Sign up

Ready to get started

Already have an account?

Sign up with email

By signing up you agree to Rappler’s Terms and Conditions and Privacy

Check your inbox

We just sent a link to your inbox. Click the link to continue registering. Can’t find it? Check your spam & junk mail.

Didn't get a link?

Join Rappler+

Join Move

How often would you like to pay?

Annual Subscription

Monthly Subscription

Your payment was interrupted

Exiting the registration flow at this point will mean you will loose your progress

Your payment didn’t go through

Exiting the registration flow at this point will mean you will loose your progress

welcome to Rappler+

welcome to Move

welcome to Move & Rappler+

Australia probes if blood clot case linked to AstraZeneca vaccine

Australia is investigating whether a blood clotting case recorded on Friday, April 2, is related to the AstraZeneca coronavirus vaccine, a health official said, raising concern in a nation where most people are expected to receive the drugmaker's shot.

A 44-year-old man was admitted to a Melbourne hospital with clotting days after receiving the AstraZeneca vaccine, suffering serious thrombosis and a low count of platelets, or blood cells that stop bleeding.

"Investigators have not at this time confirmed a causal link with the COVID-19 AstraZeneca vaccine, but investigations are ongoing," the deputy chief medical officer, Michael Kidd, told a televised briefing.

More was expected to be known on Saturday, he added.

On Thursday, Britain identified 30 cases of rare blood clot events following use of the vaccine, and several nations, including Canada, France, Germany and Spain, limited its use after similar reports.

Australian regulator the Therapeutic Goods Administration (TGA) has said previously the AstraZeneca vaccine was not tied to an increase in overall risk of blood clots, however.

In a statement on Friday, the Australian Technical Advisory Group on Immunisation said, "There is not a higher overall rate of relatively common types of blood clots (...) reported after COVID-19 vaccination."

Australia launched mass vaccinations for its 25 million people in February, with most expected to receive the University of Oxford/AstraZeneca vaccine. In late March, CSL Ltd began domestic production of 50 million doses.

Australia has been highly successful in curbing the virus with snap lockdowns, border closures and swift tracking, reporting just under 29,300 infections and 909 deaths.

It has had troubles rolling out its vaccination program, however, missing a March target by about 3.3 million doses as states and the federal government bickered over the blame.

Vaccination supplies in the northeastern state of Queensland will end within days, health officials said on Friday, adding that they were uncertain about the next delivery. – Rappler.com